MYCO-006 is an MDMA-like entactogen that is under development for the treatment of psychiatric disorders.
[1][2][3][4] It is a short-acting and fast-onset MDMA analogue.
[3][4] Based on animal studies, it is predicted that MYCO-006 will have a duration of 1 to 2 hours, about one-third the 6- to 8-hour duration of MDMA, and to onset 4 times as fast as MDMA.
[1][2] 5-BZT-MDMA (MY100) and 6-BZT-MDMA (MY101) were described in Mydecine's patent for short-acting MDMA analogues.
This psychoactive drug-related article is a stub.